brain expressed associated with NEDD4 1Genealiases: BEAN · SCA31
Q-omics provides the consensus-scored BEAN1 profile across patient tissues and cancer cell-line models. BEAN1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, BEAN1 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, BEAN1 RNA expression shows 15,403 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SCLC, THCA, and THYM as cancer lineages where BEAN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BEAN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BEAN1 survival associations across molecular data types. BEAN1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BEAN1 RNA expression–survival associations across cancer types. High BEAN1 expression shows unfavorable associations in READ and CESC, but favorable associations in SCLC, COAD, ESCA and DLBC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for BEAN1 RNA expression.
This table summarizes BEAN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for BEAN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BEAN1 shows lower tumor expression in UCEC and higher tumor expression in THCA, LUAD, COAD, BLCA and KIRP. The THCA box plot shows higher BEAN1 RNA expression in tumor versus normal tissue (log2 FC = +1.427, t-test p < 0.001).
This table shows molecular features associated with BEAN1 in patient tissues and cancer cell lines. In patient samples, BEAN1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, BEAN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
